Merz Enters Asset Purchase Agreement With a US-Based Biotech Company
2.4.2024 09:28:00 EEST | Business Wire | Press release
Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics. Closing of the transaction would significantly contribute to the accelerated growth strategy of Merz Therapeutics.
“Our specialty-neurology focused business Merz Therapeutics has developed very well in recent years. This investment would add significantly to Merz Therapeutics growth strategy and expand our portfolio in the field of movement disorders and neurodegeneration. In addition, it will strengthen the market position in North America” says Jörg Bergler, COO of the Merz Group. "We are excited about the development of Merz Therapeutics and are convinced that the purchase of the two drugs - one for the treatment of OFF phases of Parkinson's disease (PD) and one for the treatment of gait disorders in multiple sclerosis - would be of great value to both physicians and patients."
The acquisition will be processed through a court structured 363 sale process under the U.S. Bankruptcy Code, where Merz Therapeutics will provide the opening in the auction. The purchase price offered by Merz is USD 185 million. The completion of the sale process is expected in June 2024, with any sale subject to court approval.
For the family-owned Merz Group, headquartered in Frankfurt, this investment would be the third transaction in the US in just over 10 years and the second time with a NASDAQ-listed company. "Merz has grown strongly in recent years - organically, but also through strategic acquisitions, especially in North America. We have solid experience in both the acquisition and integration of US companies or products. As a German-based but global company, we are very interested in innovative acquisitions, on a global scale," concludes Jörg Bergler.
Stefan König, CEO of Merz Therapeutics, adds, “As a patient-focused, innovative company we recognize the responsibility of providing continued patient care and support for Acorda’s well-established and innovative therapies and see this as an optimal potential portfolio expansion that underscores our ambition in key therapeutic areas.”
About Merz Group
Merz Group is a global, diversified company in the healthcare sector based in Frankfurt, Germany. Family-owned for over 116 years, the company is distinguished by its commitment to innovation, long-term perspective, and focus on profitable growth. Merz Group includes the businesses Merz Aesthetics, Merz Therapeutics, Merz Consumer Care, Merz Real Estate, and Merz Financial Investments. The company employs 4,337 people (as of the 22/23 financial year) in 28 countries worldwide. To learn more, please visit www.merz.com.
About Merz Therapeutics
Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurodegenerative conditions, liver disease, and other health conditions that severely impact patients’ quality of life.
Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group. Please visit www.merztherapeutics.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401849394/en/
Contact information
Media Contact
Merz Asset Management Holding GmbH & Co. KG
Communications
Karolina Dzeko-Balke
Telephone number: +49 (0) 69 1503 2749
E-mail: karolina.dzeko-balke@merz.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments21.4.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the platform powering a nationwide network of interventional psychiatry practices. This collaboration will inform how small-to-medium sized clinics nationwide can effectively deliver novel psychedelic treatments, if FDA approved. The agreement with Osmind further expands the set of collaborations that Compass has established to inform the potential delivery of COMP360 in a broad spectrum of settings where people living with mental health conditions receive their care in the United States. Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind’s network of over 1,000 clinics comprises one of the country’s largest network of interventional psychiatry practices. Its
Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments21.4.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the platform powering a nationwide network of interventional psychiatry practices. This collaboration will inform how small-to-medium sized clinics nationwide can effectively deliver novel psychedelic treatments, if FDA approved. The agreement with Osmind further expands the set of collaborations that Compass has established to inform the potential delivery of COMP360 in a broad spectrum of settings where people living with mental health conditions receive their care in the United States. Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind’s network of over 1,000 clinics comprises one of the country’s largest network of interventional psychiatry practices. Its
Aventon Expands B2B Payment Terms Program to Germany with TreviPay21.4.2026 12:00:00 EEST | Press release
TreviPay, a global B2B payments infrastructure partner, today announced the expansion of its partnership with Aventon to support the launch of the Aventon Payment Terms program in Germany. Building on the success of Aventon’s existing program in the US and Canada, the new offering will give qualified B2B buyers in Germany access to invoicing and flexible payment terms designed to make purchasing easier and more predictable. As Aventon enters the German market and expands its presence in Europe, TreviPay will serve as the exclusive provider of payment terms for Aventon’s B2B buyers. The program is designed to help Aventon’s retail partners buy more confidently and manage working capital more effectively, while supporting the brand’s long-term growth in a new geography. By offering trade credit through TreviPay, Aventon can give retailers greater purchasing flexibility and strengthen its ability to compete in a dynamic market. TreviPay research shows 78% of B2B buyers say offering invoic
Aventon Expands B2B Payment Terms Program to Germany with TreviPay21.4.2026 12:00:00 EEST | Press release
TreviPay, a global B2B payments infrastructure partner, today announced the expansion of its partnership with Aventon to support the launch of the Aventon Payment Terms program in Germany. Building on the success of Aventon’s existing program in the US and Canada, the new offering will give qualified B2B buyers in Germany access to invoicing and flexible payment terms designed to make purchasing easier and more predictable. As Aventon enters the German market and expands its presence in Europe, TreviPay will serve as the exclusive provider of payment terms for Aventon’s B2B buyers. The program is designed to help Aventon’s retail partners buy more confidently and manage working capital more effectively, while supporting the brand’s long-term growth in a new geography. By offering trade credit through TreviPay, Aventon can give retailers greater purchasing flexibility and strengthen its ability to compete in a dynamic market. TreviPay research shows 78% of B2B buyers say offering invoic
Alpaca Expands into Europe with WealthKernel Acquisition and Launch of European Equities Trading21.4.2026 11:49:00 EEST | Press release
Alpaca, a global leader in brokerage infrastructure APIs, today announced the completion of its acquisition of European fintech WealthKernel, marking its expansion into Europe. The company also announced the initial rollout of its API-first equities trading services in Europe, enabling cross-border investing through a single integration. WealthKernel will now operate as Alpaca Europe. The acquisition gives Alpaca licensed brokerage and custody infrastructure in the UK and EU, supporting its ability to deliver investment services and expand its wealth management capabilities across the region. Built on WealthKernel’s regulatory and operational foundation, Alpaca Europe includes UK and EU licenses and local brokerage and custody infrastructure supporting products such as ISAs and SIPPs. Combined with Alpaca’s US-headquartered, licensed and regulated full-stack brokerage infrastructure, it creates a unified infrastructure layer for fintechs and financial institutions building investment p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom